Biotricity Inc. income statement BTCY

Annual Quarterly

In fiscal 2026, which ended Mar 31, 2026, Biotricity Inc. reported revenue of $16.0 million, up 16.0% from the year before. It recorded a net loss of $2.4 million. Operating income came to $1.7 million, an operating margin of 10.6%. Diluted earnings per share were -$0.12. Over the twelve months ended Jun 30, 2026, revenue was $16.4 million and the net loss was $2.7 million. Across the 8 fiscal years shown, revenue grew from $398,200 in fiscal 2019 to $16.0 million in fiscal 2026, about 69.5% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2027 Jun 30, 2026	FY 2026 Mar 31, 2026	FY 2025 Mar 31, 2025	FY 2024 Mar 31, 2024	FY 2023 Mar 31, 2023	FY 2022 Mar 31, 2022	FY 2021 Mar 31, 2021	FY 2020 Mar 31, 2020	FY 2019 Mar 31, 2019	FY 2018 Mar 31, 2018	FY 2017 Mar 31, 2017
Revenue	16 +13.4%	16 +16.0%	14 +14.3%	12 +25.2%	10 +26.0%	8 +126.0%	3 +138.7%	1 +256.0%	0	—	—
Cost of revenue	3 -3.4%	3 -5.5%	3 -13.0%	4 -11.7%	4 +36.3%	3 +45.8%	2 +126.6%	1 +175.5%	0	—	—
Gross profit	13 +18.1%	13 +22.6%	11 +26.4%	8 +53.6%	5 +19.1%	5 +259.1%	1 +162.0%	0 +711.4%	0	—	—
Research and development	3 +17.3%	3 +28.2%	2 -16.2%	3 -20.4%	3 +17.7%	3 +33.3%	2 +51.0%	1 +4.1%	1 -25.7%	2 +54.8%	1 +4.5%
Selling, general and administrative	9 -9.7%	8 -21.8%	11 -25.7%	15 -17.1%	18 -11.2%	20 +57.9%	13 +25.0%	10 +36.9%	7 +23.2%	6 +24.1%	5 +23.7%
Operating expenses	12 -4.6%	11 -13.5%	13 -24.3%	17 -17.6%	21	—	—	—	—	—	—
Operating income	2 +249.2%	2 +169.1%	-2 +72.3%	-9 +42.7%	-15	—	—	—	—	—	—
Pretax income	-3 +50.1%	-2 +71.5%	-8 +40.3%	-14 +24.5%	-19 +35.9%	-29 -88.0%	-15 -40.0%	-11 -28.8%	-9	—	—
Net income	-3 +50.1%	-2 +71.5%	-8 +40.3%	-14 +24.5%	-19 +35.9%	-29 -88.0%	-15 -40.0%	-11 -28.8%	-9 +0.4%	-9 -10.4%	-8 -7.3%
Net income to common	-3 +40.1%	-3 +73.8%	-12 +20.0%	-15 +23.6%	-20 +35.4%	-30 -83.7%	-16 -45.3%	-11	—	—	—
Basic EPS	-0.13 +44.6%	-0.12 +79.3%	-0.56 +66.6%	-1.66 +26.4%	-2.26 -239.2%	-0.67	—	—	—	—	—
Diluted EPS	-0.13 +44.6%	-0.12 +79.3%	-0.56 +66.6%	-1.66	—	—	—	—	—	—	—
Weighted average shares, basic	27 +8.1%	27 +26.9%	22 +139.4%	9 +3.8%	9 -80.9%	45	—	—	—	—	—
Weighted average shares, diluted	27 +8.1%	27 +26.9%	22 +139.4%	9	—	—	—	—	—	—	—
Other measures
Depreciation and amortization	—	0 +0.0%	0 +0.0%	0 +0.0%	0 +157.9%	0	—	—	—	—	—
EBITDA	—	2 +169.5%	-2 +72.3%	-9 +42.7%	-15	—	—	—	—	—	—
Interest coverage	0.47x	0.50x	-0.75x	—	—	—	—	—	—	—	—
Margins
Gross margin	81.47%	80.94%	76.61%	69.27%	56.46%	59.74%	37.60%	34.26%	15.03%	—	—
Operating margin	9.56%	10.57%	-17.76%	-73.18%	-159.87%	—	—	—	—	—	—
Pretax margin	-16.41%	-15.03%	-61.07%	-116.84%	-193.57%	-380.78%	-457.67%	-780.61%	-2,157.73%	—	—
Profit margin	-16.41%	-15.03%	-61.07%	-116.84%	-193.57%	-380.78%	-457.67%	-780.61%	-2,157.73%	—	—
EBITDA margin	—	10.61%	-17.72%	-73.13%	-159.81%	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as: BTCY (OTC)
Fiscal year ends: March 31
Incorporated in: NV
Headquarters: Redwood City, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1630113
Former names: METASOLUTIONS, INC. (until Jan 5, 2016)

Other Surgical & Medical Instruments & Apparatus companies

All 151 Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.